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P56 is the most abundant protein induced by interferon (IFN) treatment of human cells. To facilitate studies on its induction
pattern and cellular functions, we expressed recombinant P56 as a hexahistidine-tagged protein in Escherichia coli and
purified it to apparent homogeneity using affinity chromatography. A polyclonal antibody raised against this recombinant
protein was used to show that P56 is primarily a cytoplasmic protein. Cellular expression of P56 by transfection did not inhibit
the replication of vesicular stomatitis virus and encephalomyocarditis virus. P56 synthesis was rapidly induced by IFN-b, and
the protein had a half-life of 6 h. IFN-g or poly(A)1 could not induce the protein, but poly(I)–poly(C) or an 85-bp synthetic
double-stranded RNA efficiently induced it. Similarly, infection of GRE cells, which are devoid of type I IFN genes, by vesicular
stomatitis virus, encephalomyocarditis virus, or Sendai virus caused P56 induction. Surprisingly, Sendai virus could also
induce P56 in the mutant cell line P2.1, which cannot respond to either IFN-a/b or double-stranded RNA. Induction of P56 in
the P2.1 cells and the parental U4C cells by virus infection was preceded by activation of IRF-3 as judged by its translocation
to the nucleus from the cytoplasm. © 2000 Academic PressINTRODUCTION
Interferon (IFN) induces the transcription of many cel-
lular genes whose protein products mediate the variety
of cellular actions of IFNs (Stark et al., 1998). The most
notable among these actions is the antiviral effect (Stark
et al., 1998; Sen and Ransohoff, 1993); in IFN-treated
cells, many viruses cannot multiply effectively. Although
the exact mechanism of the antiviral effect has not been
elucidated for most viruses, it is clear that different strat-
egies are used by IFNs to inhibit the replication of dif-
ferent families of viruses (Vilcek and Sen, 1994). To un-
derstand these strategies, attention has been focused in
the recent past on individual IFN-induced proteins and
their cellular actions (Stark et al., 1998). These studies
have revealed the action of the Mx protein against influ-
enza virus and of the 2-5(A) synthetase/RNase L system
against picornaviruses (Vilcek and Sen, 1994). The IFN-
induced protein kinase PKR is also active against many
viruses under experimental conditions, but its involve-
ment in natural antiviral actions is mostly implicated by
the fact that many viruses have evolved strategies to
block PKR actions (Gale and Katze, 1998). The possible
antiviral effects of other IFN-induced proteins have not
been studied as extensively; among these other proteins
is P56, a member of a family of structurally related IFN-
induced proteins.
1 To whom reprint requests should be addressed at NC20. Fax: (216)
44-0512. E-mail: seng@ccf.org.
209P56 was one of the first IFN-inducible proteins whose
cDNA was cloned (Chebath et al., 1983; Kusari and Sen,
1986). The transcriptional regulation of the 561 gene, which
encodes P56, has been extensively studied in our labora-
tory (Bandyopadhyay et al., 1990). The 561 mRNA is induced
to a high level in IFN-treated cells. In fact, this mRNA was
recently noted to be the most abundant IFN-induced mRNA
in a gene array analysis (Der et al., 1998). The induction of
561 mRNA by IFNs is transient, and the mRNA has a
relatively short half-life (Kusari and Sen, 1986). Thus, it
seems that the P56 protein is designed to be accumulated
in IFN-treated cells to a high concentration but for a short
time, indicating that P56 may have a potential regulatory
role. The cellular functions of P56 have, however, not been
studied. In this report, we discuss the generation of appro-
priate reagents to undertake such a study, as well as the
results of experiments designed to examine the possible
antiviral effect of P56.
Although 561 mRNA was originally identified as an
IFN-inducible mRNA, we reported that it could also be
induced by infection with vesicular stomatitis virus (VSV)
or by the treatment of cells with double-stranded (ds)
RNA (Tiwari et al., 1987, 1988). We further reported that
561 mRNA induction by dsRNA is direct and does not
require IFN production as intermediates (Tiwari et al.,
1987). Furthermore, the signaling pathway used by
dsRNA for 561 mRNA induction is distinct from the one
used by IFNs (Bandyopadhyay et al., 1995). DsRNA can
induce this mRNA in cell lines lacking functional STAT1,
STAT2, P48, Tyk2, and Jak1, although each of these pro-
0042-6822/00 $35.00
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210 GUO, PETERS, AND SENteins is required by type I IFNs. Conversely, we have
reported the properties of another mutant line, P2.1, in
which the dsRNA-signaling pathway is nonfunctional
(Leaman et al., 1998). In this line, although IFN signaling
is blocked as well due to a Jak1 mutation, 561 mRNA
induction by IFN can be restored by Jak1 transfection
without alleviating the block in dsRNA signaling. Here,
we further investigated the characteristics of induction of
the P56 protein in response to IFN, dsRNA, and virus
infection and made the unanticipated observation that
virus infection can induce P56 in P2.1 cells, although
dsRNA and IFN cannot.
RESULTS
Production of recombinant P56 and its antibody
To study the pattern of induction and cellular function
of P56, we needed to generate an antibody. To obtain an
ample source of the protein itself, we expressed hexa-
histidine-tagged recombinant P56 in Escherichia coli us-
ing the pET15b plasmid. The P56 protein was tagged
with a Flag-epitope at the C-terminus to facilitate its
detection. Using a Flag-antibody, we could show that P56
was strongly induced by IPTG in pET-P56-Flag-trans-
fected E. coli (Fig. 1A). There was very little P56 before
IPTG treatment and none in vector-transfected bacteria
(Fig. 1A). The bacterially produced P56 was purified by
affinity chromatography on Ni-agarose. The purified pro-
tein was homogeneous as detected by Coomassie blue
staining (Fig. 1B).
Purified recombinant P56 was used to raise a poly-
clonal antibody in rabbits. The antiserum was character-
ized in the experiment shown in Fig. 2. In Western blot
analysis (Fig. 2A), a 56-kDa protein was detected in
IFN-treated cells but not in control cells. The antiserum
was also capable of efficiently immunoprecipitating ra-
diolabeled P56 from an extract of IFN-treated cells (Fig.
1B). Immunofluorescence assays with this antiserum re-
vealed that P56 is primarily a cytoplasmic protein (Fig.
FIG. 1. Production and purification of recombinant P56 protein. (A) pE
was induced with 1 mM IPTG. P56 protein production in bacteria was
protein was purified using Ni-chromotagraphy. Recombinant P56 prote
lane 5) or 10 ml (lane 6) of purified recombinant P56 protein was load
0 mg (lane 4) BSA. Lane 1 is a molecular weight marker (high; GIBCO
nd 43-kDa markers.1C). When extracts of IFN-treated cells were fractionated
to cytoplasmic and nuclear components, Western blot-ting with P56 antiserum confirmed that the majority of
P56 was in the cytoplasmic fraction, although some P56
was also detected in the nuclear fraction (data not
shown). The series of experiments discussed earlier
established that although untreated cells do not contain
P56, IFN treatment causes cytoplasmic accumulation of
a large quantity of this protein.
Virus replication in P56-expressing cells
Because IFN treatment causes a strong induction in
P56, we wanted to determine whether its expression, in
Flag was transfected into BL21 DE3 cells, and P56 protein production
ed using Western blotting with Flag antibody. (B) His-tagged P56-Flag
purified to homogeneity as detected by Coomassie blue staining; 5 ml
SDS–polyacrylamide gels along with 1 mg (lane 2), 5 mg (lane 3), or
The numbers on the left with arrows indicate the positions of the 68-
FIG. 2. Detection of endogenous P56 protein using P56 antibody. (A)
IFN-b (1000 U/ml) was used to treat HT1080 cells for 12 h. Treated or
ontreated cells were harvested and Western blotting was performed
sing P56 antibody to detect IFN-induced endogenous P56 protein. (B)
T1080 cells were treated with 1000 U/ml IFN-b for 12 h and pulse
labeled with 35S-methionine 1 cysteine mix for 1 h. Cells were har-
vested and extracts were made; then immunoprecipitation was per-
formed using P56 antibody to detect IFN-induced endogenous P56
protein. (C) HT1080 cells were treated with IFN in the same way as
earlier. Then cells were fixed, and immunofluorescence assay was
used to detect the subcellular location of the IFN-induced P56 proteinT-P56-
detect
in was
ed ontowith P56 antibody. Phase contrast (left) and immunofluorescence (right)
are shown.
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211INDUCTION OF P56 BY DIFFERENT STIMULIthe absence of other IFN-induced proteins, could cause
an inhibition of viral replication. For this purpose, P56
was expressed by transfecting a CMV promoter-driven
P56 expression vector and measuring the extent of rep-
lication of two cytoplasmic viruses: VSV and encephalo-
myocarditis virus (EMCV). Initially, we tried to establish
P56-overexpressing cell lines to carry out these experi-
ments. These attempts, however, failed, possibly be-
cause P56 expression slowed down cell growth (unpub-
lished observation). Because transient transfections re-
sult in only a small portion of the cell population
expressing the protein, virus replication assays could not
be performed directly with a transfected population. In-
stead, we cotransfected an expression vector of the
cell-surface protein CD20, along with the expression
vector of P56, and selected the CD20-expressing cells by
FACS. All experimental cells expressed both CD20 and
P56, as judged by immunofluorescence, whereas the
control cells expressed only CD20. These cells were
plated and then infected with VSV or EMCV. Virus repli-
cation was assessed by measuring the virus yields of the
infected cells by plaque assays. Neither VSV replication
nor EMCV replication was inhibited on P56 expression
(Table 1). In contrast, when the effects of expression of
2-5(A) synthetase were tested using a similar protocol, it
inhibited EMCV, but not VSV, replication (A. Ghosh and
G. C. Sen, unpublished observation).
Induction of P56 by IFN-b
A dose-response of IFN-b for inducing P56 is shown in
ig. 3A. As little as 10 U/ml IFN-b induced a detectable
level of P56, which was saturated beyond 100 U/ml IFN.
Induction of P56 could be detected as early as 4 h after
IFN treatment began, and the protein persisted in the
cells even 48 h later (Fig. 3B). The half-life of P56 was
determined by pulse-chase experiments. 35S-Methionine
and cysteine labeling of IFN-treated cells was followed
by chasing in unlabeled medium for different lengths of
time. Cell extract was made, P56 was immunoprecipi-
TABLE 1
Virus Replication in P56-Expressing Cells
Cells VSV (PFU/ml) EMCV (PFU/ml)
ontrol 7 3 108 7 3 107
P56 6.5 3 108 6 3 107
Note. HT1080 cells were cotransfected with pCMV-P56 or empty
vector plus pCMV-CD20 and selected for CD20-expressing cells by
FACS. Sorted cells (5 3 105) were infected with viruses at an m.o.i. of
. At 8 h postinfection, cells were frozen and thawed, and the super-
atant was collected for virus titering. Virus yield was determined by
laque assays. Average values from triplicate assays are shown.tated, and the amount of labeled P56 was determined by
gel electrophoresis followed by PhosphorImager analy-sis. This experiment showed that the half-life of the P56
protein was approximately 6 h (Fig. 4).
Induction of P56 by dsRNA
We previously reported that the mRNA encoding
P56, 561 mRNA, can be efficiently induced by dsRNA
(Tiwari et al., 1987). The same was true of the P56
protein. Western blot analysis showed that IFN-g could
nduce P56 synthesis poorly, whereas poly(I)–poly(C)
nduced it strongly and poly(A)1 did not induce it at all
(Fig. 5A). These experiments were performed with GRE
cells, which carry a deletion of the genomic locus
containing the IFN-a and IFN-b genes (Bandyo-
padhyay et al., 1995). Thus these cells could not ex-
press any type I IFN, and the observed induction of
P56 by poly(I)–poly(C) could not be due to the action of
FIG. 3. Dose-response and time course of induction of P56 by IFN-b.
(A) HT1080 cells were treated with indicated doses of IFN-b for 12 h.
hen cells were harvested, and Western blotting was performed with
56 antibody. (B) HT1080 cells were treated with 1000 U/ml IFN-b for
he indicated time periods. Cells were harvested at the various time
oints, and Western blotting was performed using P56 antibody to
etect endogenous P56.
FIG. 4. The half-life of P56 protein. HT1080 cells were treated with
1000 U/ml IFN-b for 12 h and then pulse labeled with 35S-methionine 1
cysteine mix for 1 h. Cells were chased for various time periods, and
extracts were made. Immunoprecipitation was performed with P56
antibody, and precipitated P56 protein was quantified by gel electro-
phoresis and PhosphorImager analysis.
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212 GUO, PETERS, AND SENdsRNA induction of IFN as an intermediate. Poly(I)–
FIG. 5. Induction of P56 protein by dsRNA of different lengths.
(single-stranded RNA), or 100 mg/ml dsRNA (poly(I) z poly(C)) for 8 or 18
f P56 protein by different stimuli. (B) HT1080 cells were untreated o
mmunofluorescence was performed to detect the induction of P56 p
T1080 cells were treated with 100 mg/ml poly(I)–poly(C) or 85-bp syn
performed as for B. Phase contrast (left) and immunofluorescence (rigpoly(C)-mediated induction of P56 could also be mon-
itored by immunofluorescence (Fig. 5B). Our protocolof dsRNA treatment caused the induction of P56 in all
080 cells were treated with 1000 U/ml IFN-g, 100 mg/ml poly(A)1
tern blotting was performed with P56 antibody to detect the induction
d with 100 mg/ml poly(I)–poly(C) for 12 h. Then cells were fixed, and
Phase contrast (left) and immunofluorescence (right) are shown. (C)
dsRNA for 12 h. Then cells were fixed, and immunofluorescence was
shown.(A) HT1
h. Wes
r treatecells (Fig. 5B). A synthetic dsRNA of 85 bp was as
effective in P56 induction as the commercial poly(I)–
was pe
nce (ri
213INDUCTION OF P56 BY DIFFERENT STIMULIpoly(C), which was much longer and heterogeneous in
length (Fig. 5C).
Viral induction of P56
The GRE cells were used again to determine whether
viral induction could directly induce P56 synthesis. Four
RNA viruses that have different replication strategies
were used for this assay. EMCV, VSV, and Sendai virus
could all induce P56 in GRE cells (Fig. 6), whereas
reovirus, which contains a dsRNA genome, failed to
induce it (data not shown).
Using analyses at the mRNA level, we previously es-
tablished that the signaling pathways used by IFN-a/b
and dsRNA for the induction of 561 mRNA are distinct
FIG. 6. Induction of P56 by different viruses. GRE cells were infected
of 1.0. At 24 h postinfection, cells were fixed and immunofluorescence
protein by different viruses. Phase contrast (left) and immunofluoresce(Bandyopadhyay et al., 1995). From the IFN-unresponsive
line of U4C missing Jak1, we recently isolated a mutantline, P2.1 (Leaman et al., 1998), that does not respond to
dsRNA as well. P56 induction of U4C and P2.1 in re-
sponse to various inducers was examined in Fig. 7.
Neither cell line had any detectable P56 before treat-
ment, and IFN did not induce it in either line (not shown).
As expected, dsRNA induced P56 in U4C cells but not in
P2.1 cells. Unexpectedly, Sendai virus could induce the
protein in both cell lines. To confirm the results of immu-
nofluorescence, we measured P56 induction in the two
cell lines after Sendai virus infection by Western blotting
(Fig. 8). There was no detectable P56 in either line after
mock infection. However, P56 was clearly induced in
both lines 24 and 48 h after infection. The presence of
approximately equal levels of actin in all samples served
V, EMCV, or parainfluenza 1 (Sendai) virus or mock infected at an m.o.i.
rformed with P56 antibody to detect the induction of endogenous P56
ght) are shown.with VSas an internal control. To explore the mechanism under-
lying the induction of P56 by virus infection, further ex-
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214 GUO, PETERS, AND SENperiments were carried out. Work from several laborato-
ries (Au et al., 1995; Lin et al., 1998; Navarro et al., 1998;
athelet et al., 1998; Yoneyama et al., 1998) has shown
hat the induction of IFN-sensitive genes, such as 561,
hich encodes P56, in response to virus infection re-
uires the activation of the transcription factor IRF-3.
RF-3 is constitutively present in cells in an inactive form
n the cytoplasm. On its activation, presumably through
irus-induced phosphorylation, IRF-3 translocates to the
ucleus and forms an active transcriptional complex. We
xamined in the experiments shown in Fig. 9, whether
RF-3 activation takes place in P2.1 cells. As expected,
irus infection caused IRF-3 activation and its nuclear
ranslocation in U4C cells (Figs. 9A–9D). Because P2.1
ells contain a much lower amount of IRF-3 compared
ith the U4C cells (Peters et al., 1999), a longer exposure
FIG. 7. Induction of P56 in U4C and P2.1 cells. U4C and P2.1 cell
parainfluenza 1 (Sendai) virus at an m.o.i. of 1.0 and 24 h postinfection.
to detect the induction of endogenous P56 protein in both cell lines. P
FIG. 8. Western blot analysis of P56 induction in virus-infected cells.
U4C and P2.1 cells were mock infected or infected with Sendai virus for
24 or 48 h. Cell extracts were made, and equal amounts of protein werei
i
subjected to Western blot analysis using antibodies to P56 and actin.
The positions of the two proteins are indicated on the left.ime was necessary to detect IRF-3 in P2.1 cells. Never-
heless, Sendai virus infection clearly caused nuclear
ranslocation of IRF-3 in P2.1 cells as well (Figs. 9E–9H).
hese results indicate that viral induction of P56 in both
4C and P2.1 cells is mediated by IRF-3 activation, and
ecause dsRNA cannot induce P56 in P2.1 cells, they
lso indicate a bifurcation of the dsRNA and viral signal-
ng pathways.
DISCUSSION
P56 belongs to a family of IFN-induced proteins that
ncludes P54 (Wathelet et al., 1988), P58 (Yu et al., 1997),
nd P60 (Baker et al., 1997). All these proteins are IFN
nducible and have structural homologies, but their func-
ions are unknown. The primary structure of P56 did not
eveal any functional motifs other than the presence of
ight tetratricopeptide repeats (TPRs). Because TPR mo-
ifs in other proteins have been shown to mediate pro-
ein–protein interactions (Goebl and Yanagida, 1991), we
earched for P56-interacting proteins using a yeast two-
ybrid screen. This screen revealed that P56 interacts
ith the Int-6 protein (Guo and Sen, 1997) encoded by the
nt-6 locus, whose disruption by the insertion of a mouse
ammary tumor virus genome causes breast cancer in
ice (Marchetti et al., 1995). Later, it was found that Int-6
s identical to the P48 subunit of the translation initiation
actor eIF-3 (Asano et al., 1997). The reagents generated
treated with 100 mg/ml dsRNA for 12 h, or they were infected with
ere fixed, and immunofluorescence was performed with P56 antibody
ontrast (left) and immunofluorescence (right) are shown.s weren the current study, namely pure recombinant P56 and
ts antibody, allowed us to show that P56 indeed inter-
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215INDUCTION OF P56 BY DIFFERENT STIMULIacts with eIF-3 and inhibits its function (Guo and Sen,
1998). That such an interaction is highly likely in vivo is
indicated by the observation that P56, like eIF-3, is cyto-
plasmic (Fig. 2).
To test the potential antiviral effect of P56, we had to
isolate a cell population expressing P56 in the absence
of other IFN-inducible proteins. This was achieved by
cotransfecting a cell-surface marker that was used for
FACS selection of cells. This approach was necessary
because a P56-expressing permanent cell line could not
be established. In all of the FACS-selected cells, P56 was
highly expressed. The level of P56 expression in this
population was equivalent to the level induced by 200
U/ml IFN-b as judged by Western blot analysis (data not
hown). As a result of the P56 expression, overall protein
FIG. 9. Nuclear translocation of IRF-3 upon virus infection. U4C (A–D)
and P2.1 (E–H) cells were analyzed for the subcellular localization of
IRF-3. (A and E) Mock-transfected cells. (B and F) Subcellular localiza-
tion of IRF-3 in those cells. (C and G) Cells 16 h after Sendai virus
infection. (D and H) Subcellular location of IRF-3 in them.ynthesis was inhibited by 20–30% in these cells (Guo
nd Sen, unpublished data). Despite that, however, rep-
P
sication of VSV and EMCV was unaffected (Table 1).
ecause 200 U/ml IFN strongly inhibits the replication of
oth of these viruses, it is safe to conclude from this
xperiment that the IFN-mediated inhibition of VSV and
MCV replication is not due to P56 induction. Further
tudies will be necessary to examine the effect of P56 on
he replication of other viruses.
The P56 antibody was used effectively to study the
nduction pattern of the protein in response to various
timuli. In IFN-treated cells, the protein was induced to
ts highest level in about 8 h, and then the level was
aintained for 48 h. Because the half-life of the protein
as about 6 h, this indicated its continuous synthesis in
he IFN-treated cells. dsRNA also induced the protein to
high level. Immunofluorescence assays allowed us to
tudy its induction at the single-cell level. To avoid the
omplications of intermediate IFN production, we used
he GRE cells for these studies; these cells cannot pro-
uce type I IFNs because the corresponding genes were
eleted (Bandyopadhyay et al., 1995). We used the im-
unofluorescence assay to show that like IFN treatment,
sRNA treatment also induced the protein in every cell
Fig. 5). Moreover, a dsRNA of only 85 bp was as efficient
s poly(I)–poly(C) in inducing P56. In vitro activity studies
ave shown that the 85-bp dsRNA can efficiently activate
oth 2-5(A) synthetase (Sarkar et al., 1999) and PKR
nzymes (Patel and Sen, 1994). For the former enzyme,
ven a 25-bp dsRNA is maximally effective (Sarkar et al.,
999). We can now test the cellular activity of such a
hort dsRNA on gene induction using the P56 immuno-
luorescence assay. Because these assays require only
few cells, very small amounts of dsRNA are sufficient
or them.
Among the four viruses tested for P56 induction, three
ere effective. We used Sendai virus for further studies
ecause it was the least cytopathic. How does virus
nfection induce P56 and possibly other proteins of this
amily? Clearly IFN is not involved in the process be-
ause GRE cells cannot synthesize IFNs (Fig. 6) and U4C
nd P2.1 cells cannot respond to IFNs because they lack
ak1 (Fig. 7). Could dsRNA be involved in the process?
raditionally, the induction of genes, such as IFN genes,
y viruses has been thought to be mediated by viral
sRNA intermediates. From that context, it was surpris-
ng that reovirus, which contains a dsRNA genome, was
he only one that failed to induce P56. One can speculate
hat for reovirus, the dsRNA genome is so well coated
ith viral proteins that the cellular proteins, which medi-
te dsRNA signaling, cannot come in contact with it. In
ontrast, the single-stranded RNA viruses produce
sRNA transiently during genome replication that trig-
ers the cellular response. The results shown in Fig. 7,
owever, strongly suggest that viral induction of P56 is
ndependent of dsRNA: Sendai virus could induce P56 in
2.1 cells almost as effectively as in U4C cells. We have
hown that dsRNA can enter P2.1 cells and activate PKR
a
I
t
p
t
m
u
h
i
o
t
i
m
S
i
c
r
F
g
a
v
i
v
i
o
g
s
(
b
m
a
H
c
C
u
c
(
w
D
s
f
P
f
w
p
s
h
l
(
p
E
p
B
o
216 GUO, PETERS, AND SENnormally; it, however, fails to activate nuclear factor-kB
nd IRF-3 and cannot induce transcription of 561 or
FN-b genes. In contrast, in the parental U4C cells, all of
he above processes are functional. We postulated that a
utative protein, protein X, located between PKR and the
ranscription factors in the dsRNA-signaling pathways, is
utated in P2.1 cells. Sendai virus infection apparently
sed an alternative pathway to induce P56. Thus we
ave uncovered a third possible pathway for 561 gene
nduction. Further investigation will reveal the nature of
verlaps, if any, between the viral induction pathway and
he IFN- and dsRNA-mediated induction pathways. Jak1
s obviously not needed for viral induction because it is
issing from both U4C and P2.1 cells. But are STAT1,
TAT2, P48, or Tyk2, the other proteins needed for IFN-b
signaling (Stark et al., 1998), required for virus signaling?
Similarly, the role of the proteins, such as PKR, nuclear
factor-kB, and IRF-3, that are required for dsRNA signal-
ng remains to be determined for viral signaling. It is
lear, however, that IRF-3 nuclear translocation occurs in
esponse to virus infection of both U4C and P2.1 cells.
inally, the viral functions that are required for cellular
ene induction remain an open question. Is viral RNA
nd protein synthesis required for this process? Do the
iruses carry with it an inducing agent whose internal-
zation is sufficient for this process? Alternatively, can
iral attachment to its cellular receptors trigger the gene
nduction pathway? The last possibility is an attractive
ne because of the recent report that a purified CMV
lycoprotein that binds to the viral receptor can induce
pecific cellular gene in the absence of viral infection
Boyle et al., 1999).
MATERIALS AND METHODS
Cell culture
HT1080 human fibrosarcoma (Leonard and Sen, 1997),
GRE (Bandyopadhyay et al., 1995), and U4C and P2.1
(Leaman et al., 1998) cells were all maintained in Dul-
ecco’s modified Eagle’s medium (DMEM) supple-
ented with 10% fetal bovine serum, 100 U/ml penicillin,
nd 100 mg/ml streptomycin (GIBCO BRL, Grand Island,
NY).
IFNs and poly(I)–poly(C)
Recombinant IFN-g was the gift of Genentech (South
San Francisco, CA). Human IFN-a was obtained from
offman-La Roche (Nutley, NJ). Poly(I)–poly(C) was pur-
hased from Pharmacia (Piscataway, NJ).
onstruction of P56 clones
The full-length P56 cDNA was constructed by PCR
sing an existing partial clone (unpublished data). The
DNA sequence was inserted into pBluescript KS (II)
Strategene, La Jolla, CA). The cDNA for Flag epitopeas obtained as two complementary single-stranded
NAs from Operon Technologies (Alameda, CA). The
ingle-stranded Flag DNA sequences were hybridized to
orm dsDNA and subcloned into the C-terminal end of
56 cDNA in pBluescript KS (II) with the stop codon
ollowing the Flag epitope to produce P56-Flag cDNA
as excised from pBluescript KS (II) and inserted into
ET-15b, a bacterial expression vector (Novagen, Madi-
on, WI), to produce an in-frame fusion of N-terminal
exahistidine-tagged pET-P56-Flag sequences. The full-
ength cDNA of P56 was also subcloned into pCB61
Patel et al., 1996), an eukaryotic expression vector, to
roduce pCMV-P56.
xpression and purification of recombinant P56
rotein in bacteria
pET-P56-Flag was transfected into bacterial strain
L21-DE3 (Novagen), and bacterial cells were plated
nto a Luria’s broth base 1 ampicillin (LB 1 Amp) plate.
The next day, an individual colony was picked and grown
in 5 ml of LB 1 Amp medium overnight. Bacteria were
collected by centrifugation, resuspended, and induced in
10 ml of LB with 1 mM IPTG for 3 h at 37°C for P56
production. Induced bacterial cells were spun down and
resuspended in 200 ml of 2 3 SDS sample buffer, and 20
ml was used to load onto an SDS–polyacrylamide gel,
after Western blotting analysis as described later to de-
tect P56 production using 0.6 mg/ml anti-Flag antibody
Flag probe (Santa Cruz Biotechnology, Santa Cruz, CA).
Purification was performed using Ni-chromatography as
described in the Novagen system manual. Briefly, bacte-
rial cells containing pET-P56-Flag plasmid was grown in
500 ml of LB 1 Amp culture until OD595 reached 0.8. Then
cells were suspended in 1 liter of LB plus 1 mM IPTG and
induced for 3 h at 37°C. Bacteria were collected by
centrifugation, resuspended, and sonicated in binding
buffer (5 mM imidazole, 300 mM NaCl, 20 mM Tris, pH
7.9, 0.05% Nonidet P-40, 1 mM PMSF) on ice six times
with 30 s each time and with a 30-s interval to lyse the
bacterial cells. Whole-cell lysate was centrifuged at
12,000 3 g for 1 h, and the supernatant was collected.
Then 4 ml of precharged His-bind Resin suspension
(Novagen) was added to the supernatant, and the mix-
ture was incubated at 4°C for 2 h so His-tagged P56-Flag
protein was bound to the His-bind Resin. After binding,
the resin was centrifuged at 5000 3 g at 4°C for 5 min
and washed six times with washing buffer (60 mM imi-
dazole, 300 mM NaCl, 20 mM Tris, pH 7.9, 0.05% Nonidet
P-40, 1 mM PMSF). Bound P56-Flag was eluted with 5 ml
of elution buffer (100 mM EDTA, 500 mM NaCl, 20 mM
Tris, pH 7.9) and dialyzed against 2 liters of dialysis buffer
(20 mM Tris–HCl, pH 7.5, and 20% glycerol) with three
changes every 4 h followed by a dialysis overnight.
Purified protein was concentrated using a Centriplus 10
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217INDUCTION OF P56 BY DIFFERENT STIMULIconcentrator (molecular weight cut-off, 10,000; Amicon
no. 4421) to the final concentration of 0.4 mg/ml.
ntibody production
Next 2 mg of purified recombinant P56 protein was
njected into rabbits to raise polyclonal antibody against
56. Blood samples from injected rabbits were collected
nd checked for their anti-P56 activity by Western blot-
ing.
sRNA synthesis
Synthetic dsRNA (85 bp) was made by transcribing the
ulticloning site of pBluescript KS1 as described previ-
usly (Sarkar et al., 1999).
Stimuli treatment
Different concentrations of IFN-b, 1000 U/ml IFN-g, or
00 mg/ml dsRNA [(poly(I)–poly(C) or 85-bp synthetic
dsRNA] were added to culture medium, and the cells
were treated for the desired time periods as indicated in
the figure legends.
Western blotting
Bacterial cell extract was prepared in 2 3 SDS sample
uffer as described earlier for P56 expression in bacte-
ia. Human cell extract was prepared in 1 3 lysis buffer
0.5% Nonidet P-40, 50 mM Tris–Cl, pH 8.0, 10% glycerol,
.1 mM EDTA, 300 mM NaCl, 0.4 mM PMSF, 5 mg/ml
protinin, 2.5 mg/ml pepstatin, and 1 mg/ml leupetin) for
h on ice. Then 20 ml of bacterial cell extract or 50 mg of
otal cell extract (as determined by the Bradford assay for
rotein; Bio-Rad, Hercules, CA) was loaded onto SDS–
olyacrylamide gels and transferred to polyvinylidene
ifluoride membrane (Immobilon-P; Millipore, Bedford,
A). Western blotting was performed as described pre-
iously (Leonard and Sen, 1996). Flag probe 0.6 mg/ml;
(Santa Cruz) or 1:2000 dilution of P56 antibody was used
to detect Flag-tagged protein and P56 respectively.
35S-Labeling and immunoprecipitation of proteins
HT1080 cells were seeded onto 60-mm plates; the next
ay, cells were about 80–90% confluent and treated with
000 U/ml IFN-b for 12 h if desired. Then untreated and
treated cells were washed with labeling medium (serum-
free DMEM without methionine and cysteine) twice and
pulse labeled with 150 mCi of 35S-methionine 1 cysteine
mix for 1 h in 1 ml of labeling medium. The labeling
medium was removed, the cells were harvested, and
whole-cell extracts were made as described earlier for
Western blotting analysis. Immunoprecipitation was per-
formed as follows. One milligram of extract protein (as
determined by the Bradford assay for protein; Bio-Rad)
from each sample was mixed with 1:100 dilution of P56
antibody in 500 ml of RIPA buffer (150 mM NaCl, 1%Nonidet P-40, 0.5% deoxycholic/acid, 0.1% SDS, 50 mM
Tris–Cl, pH 8.0, and 0.4 mM PMSF) for 2 h at 4°C on a
rotating wheel. Then 20 ml of protein A agarose suspen-
sion (Calbiochem, San Diego, CA) was added to the
mixture and incubated at 4°C for 1 h. The precipitates
were washed three times with RIPA buffer and resus-
pended in 2 3 SDS sample buffer. The precipitates were
loaded onto SDS–polyacrylamide gels, and P56 protein
was analyzed by PhosphorImager.
Half-life analysis
HT1080 cells were seeded onto 60-mm plates; the next
day, cells were treated with 1000 U/ml IFN-b for 12 h if
desired. Then cells were washed with labeling medium
(serum-free DMEM without methionine and cysteine)
twice and pulse labeled with 150 mCi of 35S-methio-
nine 1 cysteine mix for 1 h in 1 ml of labeling medium.
Then the labeling medium was removed, and cells were
refed with DMEM 1 10% serum medium and chased for
various time periods as described in Fig. 4 for the half-
life study. Whole-cell extract was made as described
earlier, immunoprecipitation was performed as de-
scribed earlier with P56 antibody, precipitated P56 pro-
tein was quantified by PhosphorImager, and quantified
PhosphorImager units were plotted using Microsoft
Excel.
Immunofluorescence assay for P56
Different stimulus-treated HT1080, GRE, U4C, or P2.1
cells or virus-infected GRE, U4C, or P2.1 cells as indi-
cated in different experiments were fixed with 1:1 meth-
anol–acetone and blocked in TBST 1 3% BSA 1 3%
ormal rabbit serum for 40 min at room temperature.
ells were stained with 1:2000 dilution of P56 antibody in
BST 1 3% BSA for 2 h and washed three times with
BST. Antibody staining was done with 1:2000 dilution of
ITC-conjugated goat anti-rabbit antibody (GIBCO BRL)
or 45 min and washed three times with TBST. Coverslips
ere mounted with one drop of Vectoshield (Vector),
ealed with nail polish, and examined.
solation of P56-expressing cells
pCB61 or pCMV-P56 was cotransfected with CMV-
D20 in a ratio of 8:1 into HT1080 cells in 100-mm
lates. At 18 h posttransfection, cells were trypsinized
nd incubated for 30 min with 20 ml/100-mm plate of
FITC-conjugated anti-CD20 antibody (Becton Dickin-
son Immunocytometry Systems, San Jose, CA). Then
cells were washed twice in PBS and resuspended in
DMEM. Cell sorting was performed to detect FITC-
conjugated anti-CD20 antibody for CD20 expression
by FACS.
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218 GUO, PETERS, AND SENVirus infection of P56-expressing cells and plaque
assay
Sorted vector- or P56-expressing cells (3 3 105) from
earlier were seeded onto a 6-well plate. The next day,
cells were 90% confluent, which was about 5 3 105 cells,
and were infected with VSV (Indiana) or EMCV (M. Vari-
ant, ATCC VR-1314) at an m.o.i. of 1.0 in serum-free
DMEM for 1-h absorption. Then virus was removed, and
cells were washed twice with DMEM and incubated in 2
ml of DMEM 1 10% serum at 37°C. At 8 h postinfection,
cells and medium were collected for plaque assay. For
the plaque assay, 2 ml of cells was collected, and me-
dium from earlier was frozen, thawed three times, and
spun to collect the supernatant containing viruses as the
virus stock. Virus stocks were diluted 1021 to 1029 at nine
different dilutions in triplicate in serum-free DMEM.
HT1080 cells were seeded onto a 6-well plate; the next
day, cells were 90–100% confluent (6 3 105 cells) and
ready for infection. Diluted viruses were added to
HT1080 cells in 0.5 ml of serum-free DMEM for 1 h at
37°C for absorption. Then viruses were removed, and
cells were washed once with 1 3 PBS. Medium (3 ml)
plus 0.5% agar (no. BP1423-500; Fisher Biotech, auto-
claved and warmed up to 65°C just before addition to the
cells) was added to the cell monolayer, and the 6-well
plate was left at room temperature for 10 min until the
agar solidified. The plates were transferred to 37°C, and
24 h later, plaques were counted.
Viral infection and immunofluorescence assay
GRE, U4C, or P2.1 cells were seeded onto coverslips in
6-well plates. The next day, cells were about 90–100%
confluent; then GRE cells were infected with VSV (Indi-
ana), EMCV (M. Variant, ATCC VR-1314), parainfluenza 1
(Sendai/Cantell, ATCC VR-907), or reovirus type 3 (Abney,
ATCC VR-232) and U4C and P2.1 cells were infected with
parainfluenza 1 (Sendai/Cantell, ATCC VR-907) at an
m.o.i. of 1.0 for 1 h in serum-free DMEM. Medium was
removed, and the cells were washed with DMEM and
then refed with DMEM containing 10% serum and incu-
bated for 24 h. Cells were fixed, and immunofluores-
cence was performed as described earlier to detect the
induction of P56 by different viruses.
IRF-3 translocation assay
U4C and P2.1 cells were seeded onto coverslips and,
if desired, infected with Sendai virus. Mock- or virus-
infected cells were fixed after 16 h with 4% paraformal-
dehyde in PBS for 30 min, permeabilized with 0.2% Triton
X-100 in PBS for 15 min, and blocked in PBST 1 3%
BSA 1 3% normal rabbit serum for 2 h at room temper-
ture. Cells were stained with a 1:1000 dilution of anti-
RF-3 rabbit serum (gift of Michael David) in PBST 1 3%
SA for 1 h. FITC-conjugated goat anti-rabbit stainingnd specimen mounting were performed as previously
escribed. Cells were visualized by light microscopy
ollowed by fluorescence microscopy.
ACKNOWLEDGMENTS
We thank Judith Drazba for helping us with the fluorescence micros-
copy and Michael David for the IRF-3 antibody. We also thank Arundhati
Ghosh, Deborah Vestal, Rekha C. Patel, and Michael Molstad for
helpful discussion and Scott Erme for technical assistance. The FACS
sorting facility was dedicated through a gift from the W. M. Keck
Foundation. This work was supported in part by National Institutes of
Health Grants CA-68782 and CA-62220.
REFERENCES
Asano, K., Merrick, W. C., and Hershey, J. W. (1997). The translation
initiation factor eIF3–p48 subunit is encoded by int-6, a site of
frequent integration by the mouse mammary tumor virus genome.
J. Biol. Chem. 272, 23477–23480.
Au, W. C., Moore, P. A., Lowther, W., Juang, Y.-T., and Pitha, P. M. (1995).
Identification of a member of the interferon regulatory factor family
that binds to the interferon-stimulated response element and acti-
vates expression of interferon-induced genes. Proc. Natl. Acad. Sci.
USA 92, 11657–11661.
Baker, E., de Veer, M. J., Devenish, R. J., Sutherland, G. R., and Ralph,
S. J. (1997). Interferon- and virus-inducible gene ISG-60: Map position
10q23.3. Chromosome Res. 5, 572.
Bandyopadhyay, S. K., Kalvakolanu, D. V., and Sen, G. C. (1990). Gene
induction by interferons: Functional complementation between trans-
acting factors induced by alpha interferon and gamma interferon.
Mol. Cell. Biol. 10, 5055–5063.
Bandyopadhyay, S. K., Leonard, G. T., Jr., Bandyopadhyay, T., Stark,
G. R., and Sen, G. C. (1995). Transcriptional induction by double-
stranded RNA is mediated by interferon-stimulated response ele-
ments without activation of interferon-stimulated gene factor 3.
J. Biol. Chem. 270, 19624–19629.
Boyle, K. A., Pietropaolo, R. L., and Compton, T. (1999). Engagement of
the cellular receptor for glycoprotein B of human cytomegalovirus
activates the interferon-responsive pathway. Mol. Cell. Biol. 19,
3607–3613.
Der, S. D., Zhou, A., Williams, B. R., and Silverman, R. H. (1998).
Identification of genes differentially regulated by interferon alpha,
beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci.
USA 95, 15623–15628.
Gale, M., Jr., and Katze, M. G. (1998). Molecular mechanisms of inter-
feron resistance mediated by viral-directed inhibition of PKR, the
interferon-induced protein kinase. Pharmacol. Ther. 78, 29–46.
Goebl, M., and Yanagida, M. (1991). The TPR snap helix: A novel protein
repeat motif from mitosis to transcription. Trends Biochem. Sci. 16,
173–177.
Guo, J., and Sen, G. C. (1997). The product of interferon-inducible gene
561 interacts with the nuclear Int-6 protein and relocates it to the
cytoplasm. J. Interferon Cytokine Res. 17, S68.
Guo, J., and Sen, G. C. (1998). The interferon-induced protein, P56,
binds to the P48 subunit of the translation initiation factor eFi-3 and
inhibits translation. Eur. Cytokine Network 9, P325, 94.
Kusari, J., and Sen, G. C. (1986). Regulation of synthesis and turnover of
an interferon-inducible mRNA. Mol. Cell. Biol. 6, 2062–2067.
Leaman, D. W., Salvekar, A., Patel, R., Sen, G. C., and Stark, G. R. (1998).
A mutant cell line defective in response to double-stranded RNA and
in regulating basal expression of interferon-stimulated genes. Proc.
Natl. Acad. Sci. USA 95, 9442–9447.
Leonard, G. T., and Sen, G. C. (1996). Effects of adenovirus E1A protein
on interferon-signaling. Virology 224, 25–33.
Leonard, G. T., and Sen, G. C. (1997). Restoration of interferon re-
LM
N
P
P
S
S
W
Y
219INDUCTION OF P56 BY DIFFERENT STIMULIsponses of adenovirus E1A-expressing HT1080 cell lines by overex-
pression of p48 protein. J. Virol. 71, 5095–5101.
in, R., Heylbroeck, C., Pitha, P. M., and Hiscott, J. (1998). Virus-depen-
dent phosphorylation of the IRF-3 transcription factor regulates nu-
clear translocation, transactivation potential, and proteasome-medi-
ated degradation. Mol. Cell. Biol. 18, 2986–2996.
archetti, A., Buttitta, F., Miyazaki, S., Gallahan, D., Smith, G. H., and
Callahan, R. (1995). Int-6, a highly conserved, widely expressed gene,
is mutated by mouse mammary tumor virus in mammary preneopla-
sia. J. Virol. 69, 1932–1938.
avarro, L., Mowen, K., Rodems, S., Weaver, B., Reich, N., Spector, D.,
and David, M. (1998). Cytomegalovirus activates interferon immedi-
ate-early response gene expression and interferon regulatory factor
3-containing interferon-stimulated response element-binding com-
plex. Mol. Cell. Biol. 18, 3796–3802.
atel, R. C., and Sen, G. C. (1994). Characterization of the interactions
between double-stranded RNA and the double-stranded RNA bind-
ing domain of the interferon induced protein kinase. Cell. Mol. Biol.
Res. 40, 671–682.
Patel, R. C., Stanton, P., and Sen, G. C. (1996). Specific mutations near
the amino terminus of double-stranded RNA-dependent protein ki-
nase (PKR) differentially affect its double-stranded RNA binding and
dimerization properties. J. Biol. Chem. 271, 25657–25663.
eters, K. L., Stark, G. R., and Sen, G. C. (1999). Analysis of dsRNA
signaling defects in P2.1 mutant cells. J. Interferon Cytokine Res. 19,
S131.
arkar, S. N., Bandyopadhyay, S., Ghosh, A., and Sen, G. C. (1999).
Enzymatic characteristics of recombinant medium isozyme of 29-59
oligoadenylate synthetase. J. Biol. Chem. 274, 1848–1855.en, G. C., and Ransohoff, R. M. (1993). Interferon-induced antiviral
actions and their regulation. Adv. Virus Res. 42, 57–102.Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., and
Schreiber, R. D. (1998). How cells respond to interferons. Annu. Rev.
Biochem. 67, 227–264.
Tiwari, R. K., Kusari, J., Kumar, R., and Sen, G. C. (1988). Gene induction
by interferons and double-stranded RNA: Selective inhibition by
2-aminopurine. Mol. Cell. Biol. 8, 4289–4294.
Tiwari, R. K., Kusari, J., and Sen, G. C. (1987). Functional equivalents of
interferon-mediated signals needed for induction of an mRNA can be
generated by double-stranded RNA and growth factors. EMBO J. 6,
3373–3378.
Vilcek, J., and Sen, G. C. (1994). Interferons and other cytokines. In
“Fields’ Virology” (B. N. Fields, Knipe, D. M., and Howley, P. M., Eds.),
pp. 375–399. Lippincott-Raven Publishers, Philadelphia.
Wathelet, M. G., Clauss, I. M., Content, J., and Huez, G. A. (1988). The
IFI-56K and IFI-54K interferon-inducible human genes belong to the
same gene family. FEBS Lett. 231, 164–171.
athelet, M. G., Lin, C. H., Parekh, B. S., Ronco, L. V., Howley, P. M., and
Maniatis, T. (1998). Virus infection induces the assembly of coordi-
nately activated transcription factors on the IFN-b enhancer in vivo.
Mol. Cell. 1, 507–518.
Yoneyama, M., Suhara, W., Fukuhara, Y., Fukuda, M., Nishida, E., and
Fujita, T. (1998). Direct triggering of the type I interferon system by
virus infection: Activation of a transcription factor complex containing
IRF-3 and CBP/p300. EMBO J. 17, 1087–1095.
u, M., Tong, J. H., Mao, M., Kan, L. X., Liu, M. M., Sun, Y. W., Fu, G., Jing,
Y. K., Yu, L., Lepaslier, D., Lanotte, M., Wang, Z. Y., Chen, Z., Waxman,
S., Wang, Y. X., Tan, J. Z., and Chen, S. J. (1997). Cloning of a gene
(RIG-G) associated with retinoic acid-induced differentiation of acute
promyelocytic leukemia cells and representing a new member of a
family of interferon-stimulated genes. Proc. Natl. Acad. Sci. USA 94,
7406–7411.
